Citations

Clear

9383 citation(s) found for "Thomas, PS".

Abstract 2930: Novel colorectal cancer loci in multiplex-proficient mismatch repair families
Cunningham, Julie M. , Cicek, Mine , Brooke, Fridley, Serie, Daniel, Diergaarde, Brenda , Kontriris, Theodore, Younghusband, Ban, Gallinger, Steven, Jenkins, Mark A. , Templeton, Allyson , Green, Roger, Parry, Susan, Young, Joanne , Thomas, Duncan C. , Lindor, Noralane M. , Thibodeau, Stephen N. , Goode, Ellen L. , CFR., Colon, Bamlet, William R. , Haile, Robert W. , Marchand, Loı̈c Le , Newcomb, Polly A. , Hopper, John L. , Casey, Graham , Schumacher, Fredrick R. , Chen, Zhu , Winship, Ingrid , Macrae, Finlay , Young, Graeme P. , Buchanan, Daniel D. , Bishop, D. Timothy , Potter, John D. , CFR., Colon, Jenkins, Mark A , Diergaarde, Brenda

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 2930-2930

10.1158/1538-7445.am2012-2930 Get It

Abstract A substantial proportion of familial colorectal cancer (CRC) is not a consequence of known susceptibility loci, such as mismatch repair (MMR) genes, supporting the existence of additional loci. To identify novel CRC loci, we conducted a genome-wide linkage scan in 356 white families with no evidence of defective MMR (i.e., no tumors with loss of expression of MMR proteins; no microsatellite instability (MSI)-high tumors, and no evidence of linkage to MMR genes). This represents the largest linkage analysis of proficient MMR (pMMR) familial CRC to date. Families were ascertained via the NCI-supported Colon Cancer Family Registry multi-site (Colon CFR) consortium, the City of Hope, and Memorial University of Newfoundland. A total of 1,612 individuals (average 5.0 per family, range 2-10 with an average of 2.2 affected and 2.8 unaffected individuals) were genotyped using genome-wide single nucleotide polymorphism linkage arrays; parametric and non-parametric linkage analysis used MERLIN in a priori-defined family groups. Five lod scores greater than 3.0 were observed, accounting for heterogeneity, in four chromosomal regions. The greatest lod scores were at 4q21.1 among families with mean age of diagnosis less than 50 years (dominant HLOD=4.51, α=0.84, 145.40 cM, rs10518142) and at 12q24.32 among all families (dominant HLOD=3.60, α=0.48, 285.15 cM, rs952093). Among families with four or more affected individuals and among clinic-based families, a common peak was observed at 15q22.31 (101.40 cM, rs1477798; dominant HLOD=3.07, α=0.29; dominant HLOD=3.03, α=0.32, respectively). Analysis of families with only two affected individuals yielded a peak at 8q13.2 (recessive HLOD=3.02, α=0.51, 132.52 cM, rs1319036). These linkage regions comprise previously unreported loci, supporting the hypothesis that novel loci contribute to CRC in familial pMMR cases. These loci are also largely distinct from those identified in case-control GWAS. To follow up on these findings, a custom Agilent Sure Select Target Enrichment panel has been designed for genes in three of these regions, in order to sequence probands using an Illumina HiSeq 2000. This study demonstrates the utility of family-based data and provides evidence for additional alleles for familial CRC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2930. doi:1538-7445.AM2012-2930
Abstract 2927: MicroRNA binding site polymorphisms influence ovarian cancer risk in the collaborative oncological gene-environment study
Permuth‐Wey, Jennifer, Zhihua, Chen, Birrer, M., Cunningham, Julie M. , Fenstermacher, David, Gayther, Simon A. , Gentry-Maharaj, Alexandra, Iversen, Edwin S., McLaughlin, John, Menon, Usha , Narod, Steven A. , Phelan, Catherine M., Song, Honglin , Sutphen, Rebecca , Terry, Kathryn L. , Wentzensen, Nicolas , Lancaster, Johnathan M., Cheng, Jin Q. , Berchuk, Andrew, Schildkraut, Joellen M. , Goode, Ellen L. , Sellers, Thomas A. , Lin, Hui‐Yi , Tsai, Ya-Yu , Zhihua, Chen, Chen, Y. Ann , Barnholtz‐Sloan, Jill S. , Chanock, Stephen Jacob , Cramer, Daniel W. , Fridley, Brooke L. , García‐Closas, Montserrat , Bosquet, Jesús González , Jim, Heather , McLaughlin, John, Monteiro, Álvaro N.A. , Ramus, Susan J. , Risch, Harvey A. , Tyrer, Jonathan P. , Vierkant, Robert A. , Pharoah, Paul D.P. , Menon, Usha

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 2927-2927

10.1158/1538-7445.am2012-2927 Get It

Abstract Mi(cro)RNAs are short non-coding RNA molecules that play a key role in carcinogenesis by regulating tumor suppressors and oncogenes. Published data has implicated miRNAs in ovarian cancer (OC) development and progression, and we hypothesize that single nucleotide polymorphisms (SNPs) in sites of miRNA: messenger RNA (mRNA) binding may influence OC risk by altering expression levels of targeted mRNAs. To evaluate associations between SNPs in miRNA binding sites and OC risk, we used bioinformatics tools and public databases to identify miRNA binding SNPs relevant to ovarian cancer. We then evaluated the frequency of approximately 1,100 SNPs in ∼20,000 epithelial OC cases and 20,000 controls represented in the international Collaborative Oncological Gene-environment Study. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) between genotypes and case status, with adjustment for the first five principal components representing European ancestry. Log-additive genetic models were applied to each SNP, modeling the number of copies of the minor allele. Subgroup analysis was conducted for serous adenocarcinomas, the most predominant histologic subtype of epithelial OC. Preliminary analysis of 11,215 invasive epithelial OCs and 15,910 controls included four SNPs with P<10−6 and 1 SNP with P<10−5. Analysis of 6,215 invasive serous adenocarcinomas revealed two SNPs with P<10−7 and three SNPs with P<10−6. Noteworthy is rs6104808, a C>T SNP predicted to reside in a highly conserved miRNA binding site of BTBD3 (BTB POZ domain containing 3), a transcription factor suggested to be involved in cell proliferation, cancer progression, and response to platinum-based chemotherapy. rs6104808 was associated with a decreased risk of OC overall (OR (95% CI): 0.42 (0.28-0.62), P=1.26 x 10−5)), and the association was stronger among cases with serous adenocarcinoma (OR (95% CI): 0.30 (0.17-0.50), P=9.89 x 10−6)). This represents the largest, most comprehensive epidemiologic study to date to evaluate associations between miRNA binding site SNPs and OC susceptibility. Although based on a preliminary analysis, these data suggest a significant role and putative biological mechanism for common germline variants in miRNA binding sites leading to cancer development. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2927. doi:1538-7445.AM2012-2927
BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk
Spurdle, Amanda B. , Whiley, Phillip J , Thompson, Bryony A. , Feng, Bing , Healey, Sue, Brown, Melissa A. , Pettigrew, Christopher A. , kConFab, Ausems, Margreet G.E.M. , Kattentidt-Mouravieva, A.A., Ouweland, Ans M.W. van den, Lindblom, Annika , Pigg, Maritta Hellström, Schmutzler, Rita K., Engel, Christoph , Meindl, Alfons , Caputo, Sandrine M. , Sinilnikova, Olga M., Lidereau, Rosette, collaborators, French COVAR group, Guidugli, Lucia, Hansen, Thomas van Overeem , Thomassen, Mads , Eccles, Diana M, Tucker, Kathy , Rensburg, Elizabeth J. van , Wappenschmidt, Barbara, Borg, Åke , Goldgar, David E. , Nathanson, Katherine L. , Devilee, Peter , Gómez, E. , Gerdes, Anne‐Marie , Luijt, Rob B. van der , Eccles, Diana , Mazoyer, Sylvie , Castéra, Laurent , Krieger, Sophie , kConFab, Asperen, Christi J. van , Meindl, Alfons , collaborators, French COVAR group, Couch, Fergus J. , Eccles, Diana M, Benı́tez, Javier , Domchek, Susan M. , Toland, Amanda Ewart , Vreeswijk, Maaike P.G. , Spurdle, Amanda B , van Rensburg, Elizabeth J , Eccles, Diana , van der Luijt, Rob B , Nathanson, Katherine L , Engel, Christoph , Gómez-García, Encarna B , Hansen, Thomas van Overeem , Devilee, Peter , Lindblom, Annika

Mayo Clinic

Journal of Medical Genetics | August 13, 2012 | Volume: 49 | Issue: 8 | Pages: 525-532

10.1136/jmedgenet-2012-101037 | PMID 22889855 Get It

Background Clinical classification of rare sequence changes identified in the breast cancer susceptibility genes BRCA1 and BRCA2 is essential for appropriate genetic counselling of individuals carrying these variants. We previously showed that variant BRCA1 c.5096G>A p.Arg1699Gln in the BRCA1 transcriptional transactivation domain demonstrated equivocal results from a series of functional assays, and proposed that this variant may confer low to moderate risk of cancer. Methods Measures of genetic risk (report of family history, segregation) were assessed for 68 BRCA1 c.5096G>A p.Arg1699Gln (R1699Q) families recruited through family cancer clinics, comparing results with 34 families carrying the previously classified pathogenic BRCA1 c.5095C>T p.Arg1699Trp (R1699W) mutation at the same residue, and to 243 breast cancer families with no BRCA1 pathogenic mutation (BRCA-X). Results Comparison of BRCA1 carrier prediction scores of probands using the BOADICEA risk prediction tool revealed that BRCA1 c.5096G>A p.Arg1699Gln variant carriers had family histories that were less ‘ BRCA1 -like’ than BRCA1 c.5095C>T p.Arg1699Trp mutation carriers (p<0.00001), but more ‘ BRCA1 -like’ than BRCA-X families (p=0.0004). Further, modified segregation analysis of the subset of 30 families with additional genotyping showed that BRCA1 c.5096G >A p.Arg1699Gln had reduced penetrance compared with the average truncating BRCA1 mutation penetrance (p=0.0002), with estimated cumulative risks to age 70 of breast or ovarian cancer of 24%. Conclusions Our results provide substantial evidence that the BRCA1 c.5096G>A p.Arg1699Gln (R1699Q) variant, demonstrating ambiguous functional deficiency across multiple assays, is associated with intermediate risk of breast and ovarian cancer, highlighting challenges for risk modelling and clinical management of patients of this and other potential moderate-risk variants.
Abstract 2619: Relevance of mismatch repair deficiency in ovarian cancer
Cicek, Mine S., Rumilla, Kandelaria M., Lindor, Noralane M. , Block, Matthew S. , Song, Honglin , Sellers, Thomas A. , Goode, Ellen L. , Fridley, Brooke L. , Pharoah, Paul D.P.

Mayo Clinic

Cancer Research | August 9, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 2619-2619

10.1158/1538-7445.am2012-2619 Get It

Abstract Ovarian cancer is the leading cause of death in gynecologic malignancies in the United States with most patients presenting with late stage disease; patients receive the same treatment regardless of histology or tumor characteristics. The mismatch repair (MMR) molecular pathway is well-defined and known to be involved in up to 20% of ovarian cancers; however, association of deficient v proficient MMR status (dMMR v pMMR status) with risk factors and outcome is not well understood. We are conducting extensive molecular testing of the MMR genes MLH1, MSH2, MSH3, MSH6, and PMS2 on Mayo Clinic invasive epithelial ovarian cancer cases. First, the prevalence of dMMR tumors will be estimated in ovarian cancer cases (n=496) based on loss of expression of MLH1, MSH2, MSH3, MSH6, and PMS2 determined by immunohistochemistry staining of primary antibodies using negative and positive controls. Staining of tissue microarrays (TMAs) is complete; triplicate cores will be scored independently for presence or loss of protein expression by a board-certified pathologist. Second, for those dMMR cases, the possible cause of MMR deficiency will be evaluated considering germline and somatic mutations. The loss of expression of each protein will be characterized as germline if a deleterious mutation is present in peripheral blood or somatic if the pathogenic mutation is only present in tumor tissue. In cases with MLH1 loss somatic hypermethylation will also be considered. Analysis of germline mutation data will include all 496 cases and somatic mutations data will include a subset of cases tested with frozen tumor DNA (n=292) using Fluidigm access array targeted resequencing. Third, the clinical features of dMMR disease will be compared to those of pMMR; in particular, age at diagnosis, histopathology, and disease outcome. Among cases in this analysis, the majority have high-grade serous disease with a mean age at diagnosis of 61 years, about half had recurrence or progression (n=243) of which two-thirds (n=167) are deceased. Finally, known and suspected ovarian cancer risk factors (family history, smoking, body mass index, parity, use of hormone therapy, and genetic variation in susceptibility loci at 2q31, 3q25, 8q24, 9p22, 17q21, and 19p13) will be analyzed by MMR phenotype. Risk factor questionnaire data is available on 462 cases (93%), as well as 737 population controls with germline genome-wide genotype data. About half of the cases (n=231) report a 1st or 2nd degree family member with breast or ovarian cancer. Given the limited knowledge about ovarian cancer etiology and the poor prognosis of advanced disease, it is very important to study risk factors with this molecular subtype. The ovarian cancer dMMR phenotype may have distinct clinicopathological features that could guide risk stratification and be useful in diagnostics and therapeutics. This is the largest study characterizing MMR in an ovarian cancer population to date. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2619. doi:1538-7445.AM2012-2619
Abstract 2603: Subtype-specific ovarian cancer risk associated with SNPs in IL1A
Charbonneau, Bridget, White, Kristin L., Schildkraut, Joellen M. , Palmieri, Rachel T., Iversen, Ed , Rider, David N., Cicek, Mine S., Sutphen, Rebecca , Birrer, Michael J. , Song, Honglin , Gayther, Simon A. , Wentzensen, Nicolas , Phelan, Catherine M., Cunningham, Julie M. , Sellers, Thomas A. , Goode, Ellen L. , Berchuck, Andrew , Vierkant, Robert A. , Pharoah, Paul D.P. , Tyrer, Jonathan P. , Ramus, Susan J. , Yang, Hannah , García‐Closas, Montserrat , Fridley, Brooke L.

Mayo Clinic

Cancer Research | August 9, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 2603-2603

10.1158/1538-7445.am2012-2603 Get It

Abstract As pathways of the immune system play an important role in multiple malignancies, we assessed the association between single-nucleotide polymorphisms (SNPs) in inflammation-related genes and risk of ovarian cancer in a multi-site case-control study. Using a custom array, we genotyped 930 epithelial ovarian cancer cases and 1,037 controls for SNPs in ALOX12, ALOX15, ALOX5, CCL11, CCL2, CCL3, CCR3, CRP, CXCL16, IL10, IL15RA, IL18, IL1A, IL1B, IL1RN, IL4R, IL6, IL6R, IL7R, IL8RA, IL8RB, IL9, NOS3, PTGS1, PTGS2, TLR2, and TNF. After analysis by logistic regression, SNPs with p&lt;0.10 were evaluated in an independent data set of 3,143 cases and 2,102 controls from the Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) collaboration. Combined analysis revealed association with interleukin 1, alpha (IL1A) SNPs (rs17561 and rs4848300, r2=0.990, p=0.005) which varied by histological subtype (heterogeneity p=0.03). For example, IL1A rs17561, which results in a missense change in amino acid at position 114 and correlates with multiple inflammatory phenotypes, was inversely associated with risk of clear cell, mucinous, and endometrioid subtypes, but not with the serous subtype (Table 1). Additional data on IL1A rs17561 in an even larger collection of ovarian cancer cases and controls are pending and will be analyzed soon. We also found that genotype at rs1864414 in ALOX5 (arachidonate 5-lipoxygenase) was associated with decreased risk combined across subtypes (OR 0.86, 95% CI 0.78-0.95; p=0.002). Thus, inherited variation in IL1A and ALOX5 appears to have a role in ovarian cancer risk, though it is limited to rarer subtypes for IL1A. These data add to existing literature on the importance of inflammation in tumorigenesis and growing evidence of subtype-specific traits in ovarian cancer and may provide important clues on prevention. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2603. doi:1538-7445.AM2012-2603
Abstract 5518: Clinicopathologic associations with colorectal cancer molecular pathways in a cohort study of older women
Sammader, N Jewel, Tillmans, Lori S. , Wang, Alice H., Weisenberger, Daniel J. , Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Vierkant, Robert A. , Laird, Peter W. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Slager, Susan L. , Cerhan, James R. , Limburg, Paul J.

Mayo Clinic

Cancer Research | August 9, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 5518-5518

10.1158/1538-7445.am2012-5518 Get It

Abstract Background: Colorectal cancer (CRC) is a molecularly heterogeneous disease. Three molecular pathways (traditional, serrated and alternate) have been recently proposed based on integrated combinations of microsatellite instability (MSI), CpG island methylation phenotype (CIMP), BRAF mutation, and KRAS mutation status (Gastroenterol 2010;138:2088-2100). To our knowledge, clinicopathologic associations with these CRC pathways have not been previously described. Methods: Data and tissue resources were obtained from the population-based Iowa Women's Health Study, which recruited 41,836 randomly selected women, ages 55-69 years, at study entry (1986). Incident CRC cases were ascertained by annual linkage with the Iowa Cancer Registry. Archived, paraffin-embedded tissue specimens were collected from 732 CRC cases diagnosed through 12/31/2002. Established laboratory methods were used to characterize CRC cases by MSI (MSS/MSI-L or MSI-H), CIMP (neg, low, or high), BRAF mutation (wt or mut), and KRAS mutation (wt or mut) status. Molecular pathways were defined as: traditional (MSS/MSI-L, CIMP-neg, BRAF wt, and KRAS wt); serrated (any MSI, CIMP-high, BRAF mut, and KRAS wt), alternate (MSS/MSI-L, CIMP-low, BRAF wt, and KRAS mut), or other pathway. Chi-square tests and analyses of variance were used to compare clinicopathologic features at CRC presentation (age, anatomic subsite, tumor grade, and SEER stage) across the molecular pathways. Results: Comlete and informative MSI, CIMP, BRAF and KRAS data were obtained for 491/732 (67%) CRC cases. Clinicopathologic associations are shown in the Table. Conclusions: These data suggest that distributions of age at diagnosis, subsite, and tumor grade, but not SEER stage, differ across the traditional, serrated, and alternate carcinogenic pathways, which may have implications for molecularly-targeted CRC prevention and/or therapy strategies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5518. doi:1538-7445.AM2012-5518
Abstract 4492: Colorectal cancer survival by molecular subtypes in a population-based cohort of older women
Tillmans, Lori S. , Wang, Alice H., Samadder, N. Jewel , Weisenberger, Daniel J. , Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Vierkant, Robert A. , Laird, Peter W. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Slager, Susan L. , Cerhan, James R. , Limburg, Paul J.

Mayo Clinic

Cancer Research | August 9, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 4492-4492

10.1158/1538-7445.am2012-4492 Get It

Abstract Background: Despite recent advances in prevention and therapy, colorectal cancer (CRC) continues to account for nearly 50,000 deaths per year in the US. TNM stage is the current CRC prognostic standard, yet within-stage prognostic heterogeneity is well documented. Microsatellite instability (MSI), CpG island methylation phenotype (CIMP), and BRAF- and KRAS-mutation status represent candidate prognostic markers. However, associations between these markers and CRC survival have not been described in a population-based setting. Methods: Data and tissue resources were obtained from the Iowa Women's Health Study (IWHS), which recruited 41,836 women, ages 55-69 years, at study entry (1986). Incident CRC cases were ascertained by annual linkage with the Iowa Cancer Registry. Archived, paraffin-embedded tissue specimens were collected from 732 representative CRC cases diagnosed through 12/31/2002. Established laboratory methods were used to characterize CRC cases: MSI-H or MSS/MSI-L (by instability in β3 vs. &lt;3 out of 10 markers, respectively); CIMP+ or CIMP− (by promoter hypermethylation in β3 vs. 0-2 out of 5 genes, respectively); BRAFwt or BRAFmut (by fluorescent allele specific PCR to detect the V600E point mutation in exon 15); and KRASwt or KRASmut (by direct sequence analysis of codons 12 and 13 in exon 2). Cox regression models were fit to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for time to death of any cause adjusted for age, stage, grade, and treatment status. Results: CRC cases with informative molecular marker data ranged from 515/732 (70%) for KRAS to 548/732 (75%) for MSI status. Mean follow-up was 4.4 years for deceased individuals and 11.2 years for women alive at last contact. After multivariable adjustment, both MSS/MSI-L (p=0.004) and KRASmut (p=0.048) tumors were associated with poorer survival. Survival did not significantly differ across levels of CIMP and BRAF status. Conclusions: MSI and KRAS status may influence CRC survival among older women. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4492. doi:1538-7445.AM2012-4492
Genetic variants associated with myocardial infarction in the PSMA6 gene and Chr9p21 are also associated with ischaemic stroke
Soto‐Ortolaza, Alexandra I., Diehl, Nancy N. , Rayaprolu, Sruti , Brott, Thomas G. , Meschia, J. F., Ross, Owen A. , Soto‐Beasley, Alexandra I. , Heckman, Michael G. , Wszołek, Zbigniew K. , Ross, Owen A , Beasley, Alexandra I

Mayo Clinic

European Journal of Neurology | August 7, 2012 | Volume: 20 | Issue: 2 | Pages: 300-308

10.1111/j.1468-1331.2012.03846.x | PMID 22882272 Get It

BackgroundIschaemic stroke shares common traditional risk factors with coronary artery disease (CAD) and myocardial infarction (MI). This study evaluated whether genetic risk factors for CAD and MI also affect susceptibility to ischaemic stroke in Caucasians and African Americans.MethodsIncluded in the study were a Caucasian series (713 ischaemic stroke patients, 708 controls) and a small African American series (166 ischaemic stroke patients, 117 controls). Twenty single‐nucleotide polymorphisms (SNPs) previously shown to be associated with CAD or MI were genotyped and assessed for association with ischaemic stroke and ischaemic stroke subtypes using odds ratios (ORs) from multivariable logistic regression models.ResultsIn Caucasians, four SNPs on chromosome 9p21 were significantly associated with risk of cardioembolic stroke, the strongest of which was rs1333040 (OR 1.55, P = 0.0007); similar but weaker trends were observed for small vessel stroke, with no associations observed regarding large vessel stroke. Chromosome 9p21 SNPs were also associated with risk of ischaemic stroke in African Americans (rs1333040, OR 0.65, P = 0.023; rs1333042, OR 0.55, P = 0.070; rs2383207, OR 0.55, P = 0.070). The PSMA6 SNP rs1048990 on chromosome 14q13 was associated with overall ischaemic stroke in both Caucasians (OR 0.80, P = 0.036) and African Americans (OR 0.31, P = 0.020).ConclusionsOur results provide evidence that chromosome 9p21 variants are associated with cardioembolic ischaemic stroke in Caucasians and with overall ischaemic stroke in African Americans. The PSMA6 variant rs1048990 also appears to affect susceptibility to ischaemic stroke in both populations. These findings require validation, particularly the preliminary findings regarding African Americans given the small size of that series.
Correlation between Left Ventricular Global and Regional Longitudinal Systolic Strain and Impaired Microcirculation in Patients with Acute Myocardial Infarction
Løgstrup, Brian Bridal , Høfsten, Dan Eik , Christophersen, Thomas B., Møller, Jacob Eifer , Bøtker, Hans Erik , Pellikka, Patricia A. , Egstrup, Kenneth , Pellikka, Patricia A

Mayo Clinic

Echocardiography | August 3, 2012 | Volume: 29 | Issue: 10 | Pages: 1181-1190

10.1111/j.1540-8175.2012.01784.x | PMID 22862151 Get It

Objectives: We investigated the correlation between left ventricular global and regional longitudinal systolic strain (GLS and LRS) and coronary flow reserve (CFR) assessed by transthoracic echocardiography (TTE) in patients with a recent acute myocardial infarction (AMI). Furthermore, we investigated if LRS and GLS imaging is superior to conventional measures of left ventricle (LV) function. Methods: In a consecutive population of first time AMI patients, who underwent successful revascularization, we performed comprehensive TTE. GLS and LRS were obtained from the three standard apical views. Assessment of CFR by TTE was performed in a modified apical view using color Doppler guidance. Results: The study population consisted of 183 patients (51 females) with a median age of 63 [54;70] years. Eighty‐nine (49%) patients had a non‐ST elevation myocardial infarction and 94 (51%) patients had a ST elevation myocardial infarction. The GLS was −15.2 [−19.3;−10.1]% in the total population of 183 patients. Total wall motion score index (WMSI) in the population was 1.19 [1;1.5]. Eighty‐five patients suffered from culprit lesion in left anterior descending artery (LAD). The CFR in these patients was 1.86 [1.36;2.35] and the GLS was −14.3 [−18.9; −9.8]%. A significant difference was observed in the LRS in LAD territory in culprit LAD infarction patients with a CFR ≤ 2 (−9.6 [−13.77;−6.44]) compared with the LRS in LAD territory in culprit LAD infarction patients with a CFR > 2 (−19.33 [−21.1;−16.5]), P < 0.0001. We found no significant difference between WMSI in LAD territory in culprit LAD infarction patients with a CFR ≤ 2 (1.56 [1.06;2.23]) compared with WMSI in LAD territory in culprit LAD infarction patients with a CFR > 2 (1.37 [1.03;2.11]); P = 0.18. The same pattern was observed in both circumflex coronary artery (CX) and right coronary artery (RCA) territories. In the total population, we found a strong correlation between CFR and GLS (r = −0.85, P < 0.0001). This was also seen in the multivariate regression model adjusting for possible confounders including WMSI (P < 0.001). Conclusion: In this study, we have shown a close association between myocardial deformation in patients with a recent AMI and the degree of diminished microcirculation. We found that both GLS and LRS correlated with CFR. We conclude that GLS and LRS are significantly better tools to assess impaired CFR and LV function after a recent AMI, than conventional echocardiographic measurements.